Department of Neurology, The Third Affiliated Hospital of Guangxi University of Chinese Medicine, Liuzhou Traditional Chinese Medical Hospital, Liuzhou 545000, China.
Department of Oncology, The Third Affiliated Hospital of Guangxi University of Chinese Medicine, Liuzhou Traditional Chinese Medical Hospital, Liuzhou 545000, China.
Comput Math Methods Med. 2022 Dec 17;2022:2940654. doi: 10.1155/2022/2940654. eCollection 2022.
epatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality worldwide. Currently, the prevention and treatment of HCC remains a major challenge. As a traditional Chinese medicine (TCM) formula, Ruangan Lidan decoction (RGLD) has been proved to own the effect of relieving HCC symptoms. However, due to its biological effects and complex compositions, its underlying mechanism of actions (MOAs) have not been fully clarified yet. In this study, we proposed a pharmacological framework to systematically explore the MOAs of RGLD against HCC. We firstly integrated the active ingredients and potential targets of RGLD. We next highlighted 25 key targets that played vital roles in both RGLD and HCC disease via a protein-protein interaction (PPI) network and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Furthermore, an ingredient-target network of RGLD consisting of 216 ingredients with 306 targets was constructed, and multilevel systems pharmacology analyses indicated that RGLD could act on multiple biological processes related to the pathogenesis of HCC, such as cellular response to hypoxia and cell proliferation. Additionally, integrated pathway analysis of RGLD uncovered that RGLD might treat HCC through regulating various pathways, including MAPK signaling pathway, PI3K/Akt signaling pathway, TNF signaling pathway, and ERBB signaling pathway. Survival analysis results showed that HCC patients with low expression of VEGFA, HIF1A, CASP8, and TOP2A were related with a higher survival rate than those with high expression, indicating the potential clinical significance for HCC. Finally, molecular docking results of core ingredients and targets further proved the feasibility of RGLD in the treatment of HCC. Overall, this study indicates that RGLD may treat HCC through multiple mechanisms, which also provides a potential paradigm to investigate the MOAs of TCM prescription.
肝细胞癌(HCC)是全球癌症死亡的主要原因之一。目前,HCC 的预防和治疗仍然是一个主要挑战。作为一种中药(TCM)配方,软肝利胆汤(RGLD)已被证明具有缓解 HCC 症状的作用。然而,由于其生物效应和复杂的成分,其作用机制(MOAs)尚未完全阐明。在这项研究中,我们提出了一个药理学框架,系统地探讨了 RGLD 治疗 HCC 的 MOAs。我们首先整合了 RGLD 的活性成分和潜在靶点。接下来,我们通过蛋白质-蛋白质相互作用(PPI)网络和京都基因与基因组百科全书(KEGG)途径富集分析,突出了 25 个在 RGLD 和 HCC 疾病中都发挥重要作用的关键靶点。此外,构建了一个由 216 种成分和 306 个靶点组成的 RGLD 成分-靶点网络,多层次系统药理学分析表明,RGLD 可以作用于与 HCC 发病机制相关的多个生物学过程,如细胞对缺氧的反应和细胞增殖。此外,对 RGLD 的综合途径分析表明,RGLD 可能通过调节多种途径来治疗 HCC,包括 MAPK 信号通路、PI3K/Akt 信号通路、TNF 信号通路和 ERBB 信号通路。生存分析结果表明,VEGFA、HIF1A、CASP8 和 TOP2A 表达水平低的 HCC 患者的生存率高于表达水平高的患者,这表明其对 HCC 具有潜在的临床意义。最后,核心成分和靶点的分子对接结果进一步证明了 RGLD 治疗 HCC 的可行性。总之,这项研究表明,RGLD 可能通过多种机制治疗 HCC,这也为研究 TCM 处方的 MOAs 提供了一个潜在的范例。